| HOME >> BIOLOGY >> TECHNOLOGY |
CALGARY, Nov. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia." The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing.
"This patent represents a significant expansion of our intellectual property portfolio," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The claims cover additional pathways whereby tumours can become susceptible to reovirus infection and cell death."
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.
This news release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including among others, the Company's belief as
to the importance of the issuance of this patent, the safety and efficacy
of the reovirus, the Company's expectations as to the potential
applications of the patented technology and other statements relating to
anticipated developments in the Company's business and technologies,
involve known and unknown risks and uncertainties that could cause the
Company
'/>"/>
| SOURCE Oncolytics Biotech Inc. Copyright©2007 PR Newswire. All rights reserved |